Attached files
| file | filename |
|---|---|
| EX-23.3 - ADMA BIOLOGICS, INC. | e617455_ex23-3.htm |
| EX-23.1 - ADMA BIOLOGICS, INC. | e617455_ex23-1.htm |
| EX-5.1 - ADMA BIOLOGICS, INC. | e617455_ex5-1.htm |
| S-1/A - ADMA BIOLOGICS, INC. | e617455_s1a-adma.htm |
CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM
We consent to the incorporation by reference in Form S-1/A (File No. 333-220910) of ADMA Biologics, Inc. of our report, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, dated March 14, 2017 relating to our audit of the carve-out financial statements of Therapy Business Unit of Biotest Pharmaceutical Corporation, which comprise of the carve-out balance sheet as of December 31, 2016 and the related carve-out statements of operations, changes in invested equity and cash flow for the year then ended, which report is included in the Form 8-K/A filed on July 28, 2017 and Proxy Statement of ADMA Biologics, Inc. We also consent to the reference to our firm under the caption “Experts”.
/s/ CohnReznick LLP
Roseland, New Jersey
November 3, 2017